Search results for "complete remission"

showing 10 items of 24 documents

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

2015

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

0301 basic medicineOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BPolymorphism Single Nucleotide03 medical and health sciencesRemission induction0302 clinical medicinehemic and lymphatic diseasesInternal medicinemental disordersGeneticsOverall survivalHumansMedicineSurvival ratePharmacologybusiness.industryRemission InductionComplete remissionMyeloid leukemiaSurvival RateLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisMeta-analysisMolecular MedicinebusinessThe Pharmacogenomics Journal
researchProduct

The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predic…

2016

Abstract Introduction: Patients with RR-AML, particularly older adults, have dismal outcomes and limited therapy options. Given low response rates and high toxicity with salvage intensive chemotherapy, and frequent ineligibility for allogeneic stem cell transplantation (alloSCT), many patients are treated with HMAs. Robust data regarding use of HMAs in AML predominates in the frontline setting, while their use in RR-AML has limited supportive data. Here wesought to analyze theoutcomes and their predictors in patients with RR-AML treated with HMAs. Methods:We collected data, spanning a period from 2006 to 2016, from 7 centers in the United States and 4 centers in Europe regarding patients tr…

0301 basic medicinemedicine.medical_specialtybusiness.industryImmunologyComplete remissionDecitabineCell BiologyHematologyBiochemistryTransplantationClinical trial03 medical and health sciences030104 developmental biology0302 clinical medicineRefractoryInterquartile range030220 oncology & carcinogenesisInternal medicineCohortmedicineIn patientbusinessmedicine.drugBlood
researchProduct

Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute …

2014

Abstract Background:Despite recent advances in identifying novel molecular targets in AML patients, intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) still remains a cornerstone of AML therapy. However, outcome of HSCT depends on the availability of a donor and the donor type. Prior studies comparing HSCT from HLA-matched related donors (MRD) with matched unrelated donors (MUD), demonstrated conflicting results with regards to outcome. These conflicting results might be attributed to the genetic heterogeneity of AML. Aims:To analyze outcome with respect to donor type of 952 AML patients who received HSCT in first complete remission (CR) and were tr…

0303 health sciencesmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologySignificant differenceComplete remissionMyeloid leukemiaCell BiologyHematologyHematopoietic stem cell transplantationBiochemistry3. Good healthTransplantation03 medical and health sciences0302 clinical medicineRisk groupsInternal medicineMolecular targetsmedicineCumulative incidencebusiness030304 developmental biology030215 immunologyBlood
researchProduct

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup …

2016

Abstract Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high remission and survival rates coupled with significantly reduced myelosuppression. Recent results of the APL0406 trial by the GIMEMA-AMLSG-SAL study groups showed that the combination of ATRA and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in front-line therapy of low/intermediate risk acute promyelocytic leukemia (APL). The implications of these results for the clinical practice of APL patients in Germany …

Acute promyelocytic leukemiaChemotherapyPediatricsmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyComplete remissionCell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenRegimenchemistry.chemical_compoundchemistryMedicineCumulative incidenceObservational studyArsenic trioxidebusinessneoplasmsBlood
researchProduct

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group stu…

2005

Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies. However, the choice and application of the criteria for a haematological CR can often become a subject of debate because of regeneration more than 5% blasts may be present at the time of response evaluation; platelet and neutrophil recovery may be incomplete and marrow cellularity can vary. This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols. Patients with < or =5% blasts showed the best overall survival (OS) and the lowest relapse risk …

AdultMaleRiskmedicine.medical_specialtyPathologyAdolescentcomplete remissionMINIMAL RESIDUAL DISEASEDIAGNOSISGastroenterologyTHERAPYDisease-Free SurvivalAMLRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPlateletacute myeloid leukaemiaLymphocyte CountProportional Hazards ModelsrevisedHematologycriteriaProportional hazards modelbusiness.industryINDUCTIONRemission InductionCancerHematologyMiddle AgedCOLONY-STIMULATING FACTORmedicine.diseaseMinimal residual diseaseCANCERHIGH-DOSE CYTARABINELeukemiamedicine.anatomical_structureLeukemia MyeloidAcute DiseaseFemaleBone marrowbusinessBritish Journal of Haematology
researchProduct

Impaired conflict resolution and vigilance in euthymic bipolar disorder.

2015

Abstract Difficulty attending is a common deficit of euthymic bipolar patients. However, it is not known whether this is a global attentional deficit or relates to a specific attentional network. According to the attention network approach, attention is best understood in terms of three functionally and neuroanatomically distinct networks-alerting, orienting, and executive control. In this study, we explored whether and which of the three attentional networks are altered in euthymic Bipolar Disorder (BD). A sample of euthymic BD patients and age-matched healthy controls completed the Attention Network Test for Interactions and Vigilance (ANTI-V) that provided not only a measure of orienting…

AdultMalemedicine.medical_specialtyBipolar Disordermedia_common.quotation_subjectAudiologyalerting; attention network test (ant); bipolar disorders; executive control; orienting; vigilance; psychiatry and mental health; biological psychiatryExecutive Functionbiological psychiatryvigilanceOrientationConflict resolutionattention network test (ant)medicineReaction TimeHumansAttentionBipolar disordermedia_commonNegotiatingorientingAttentional controlComplete remissionIndependent measureCognitionMiddle Agedmedicine.diseaseFunctional recoverypsychiatry and mental healthAffectexecutive controlbipolar disordersalertingFemalePsychologyArousalCognitive psychologyVigilance (psychology)Psychiatry research
researchProduct

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myelo…

2022

Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from…

AdultSirolimusTransplantationBLOODTransplantation ConditioningCONDITIONING INTENSITYGVHD PROPHYLAXISHematopoietic Stem Cell TransplantationGraft vs Host Disease1ST COMPLETE REMISSIONHematologyMycophenolic AcidOPEN-LABELDIAGNOSISPatologiaHEMATOLOGIC MALIGNANCIESEUROPEAN-SOCIETYLeukemia Myeloid AcuteRISK INDEXHumansMARROW-TRANSPLANTATIONUnrelated DonorsCyclophosphamideRetrospective StudiesBone marrow transplantation
researchProduct

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

2021

Abstract Introduction/Background: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. Patients and Methods: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. Results: The 2-year relapse incide…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTransplantation ConditioningHaploidentical transplantationGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/CancerGraft-versus-host diseaseInternal medicinemedicineHumansTransplantation HomologousComplete remissionComputingMilieux_MISCELLANEOUSAgedRetrospective StudiesAged 80 and overUnivariate analysisCMV positivitybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyTotal body irradiationPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMinimal residual diseaseAllogeneic stem cell transplantationTransplantationLeukemia Myeloid AcuteGraft-versus-host diseaseOncologyTreatment-related mortalityAllogeneic stem cell transplantation; CMV positivity; Complete remission; Graft-versus-host disease; Haploidentical transplantation; Treatment-related mortalitybusiness
researchProduct

MR-Mammographie zur Responsekontrolle bei primärer Chemobrachytherapie des BET-inoperablen Mammakarzinoms

2001

Ziel: Evaluierung (1) moglicher storender Effekte neoadjuvanter Chemobrachytherapie auf die MR-Mammographie, (2) der Eignung der MRM zur Bestimmung der Resttumorgrose nach Therapie und (3) der Eignung der MRM zur Prognose des Gesamtansprechens nach den ersten Therapiezyklen. Methoden: 14 Patientinnen, die an einer praoperativen Tumorreduktionstherapie (4 Zyklen Chemotherapie kombiniert mit interstitieller Radiotherapie) teilnahmen, wurden mittels dynamischer MR-Mammographie (1 T, zeitliche Auflosung 93 s, raumliche Auflosung 1,9 mm, 0,1 mmol/kg GdDTPA) vor Therapie, nach den ersten beiden Chemotherapiezyklen, nach der Radiotherapie und dem dritten Zyklus sowie nach Therapieabschluss untersu…

End of therapybusiness.industrymedicine.medical_treatmentSingle tumorComplete remissionTumor responseRadiation therapyInterstitial radiotherapyMedicineRadiology Nuclear Medicine and imagingbusinessNuclear medicineNeoadjuvant therapyMr mammographyRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Tinea imbricata in Papua-Neuguinea: Behandlungsversuch mit Griseofulvin und Haloprogin bei einer Population des Gogol-Valley, Madang Province

2009

Zusammenfassung: In zwei Dorfern des Gogol Valley (Papua-Neuguinea) wurden satliche 47 an Tinea imbricata erkrankten Personen erfas, wovon 39 einer Griseofuhin®- bzw. Mycan-den®-Therapie oder Kombination zugefuhrt wurden. Die Zuweisung zu den unterschiedlichen Behandlungsgruppen erfolgte anhand des Alters und des prozentualen Befalls der Korperoberflache. Die Therapiedauer betrug maximal 4 Wochen, der Beobachtungszeitraum insgesamt 6 Wochen. Eine Remission des Hautbefalls erfolgte fur beide Therapeutika von der 2. Behand-lungswoche an. Rezidive traten jedoch schon 1 Woche nach Therapieende auf. Es konnten Unterschiede in der Altersverteilung der Erkrankten in beiden Dorfern festgestellt wer…

Gynecologymedicine.medical_specialtybusiness.industryComplete remissionNew guineaDermatologyGeneral Medicinemedicine.diseaseGriseofulvinSkin symptomsSurgerychemistry.chemical_compoundInfectious DiseaseschemistrymedicineAge distributionTinea imbricatabusinessSkin lesionHaloproginmedicine.drugMycoses
researchProduct